AU2013282400B2 - Cells for producing recombinant iduronate-2-sulfatase - Google Patents

Cells for producing recombinant iduronate-2-sulfatase Download PDF

Info

Publication number
AU2013282400B2
AU2013282400B2 AU2013282400A AU2013282400A AU2013282400B2 AU 2013282400 B2 AU2013282400 B2 AU 2013282400B2 AU 2013282400 A AU2013282400 A AU 2013282400A AU 2013282400 A AU2013282400 A AU 2013282400A AU 2013282400 B2 AU2013282400 B2 AU 2013282400B2
Authority
AU
Australia
Prior art keywords
cell
protein
seq
nucleic acid
fge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013282400A
Other languages
English (en)
Other versions
AU2013282400A1 (en
Inventor
Ferenc Boldog
Michael Heartlein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2013282400A1 publication Critical patent/AU2013282400A1/en
Priority to AU2016200460A priority Critical patent/AU2016200460B2/en
Application granted granted Critical
Publication of AU2013282400B2 publication Critical patent/AU2013282400B2/en
Priority to AU2018200710A priority patent/AU2018200710B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE HUMAN GENETIC THERAPIES, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2013282400A 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase Active AU2013282400B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016200460A AU2016200460B2 (en) 2012-06-29 2016-01-27 Cells for producing recombinant iduronate-2-sulfatase
AU2018200710A AU2018200710B2 (en) 2012-06-29 2018-01-30 Cells for producing recombinant iduronate-2-sulfatase

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29
US61/666,719 2012-06-29
PCT/US2013/048571 WO2014005019A2 (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016200460A Division AU2016200460B2 (en) 2012-06-29 2016-01-27 Cells for producing recombinant iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
AU2013282400A1 AU2013282400A1 (en) 2015-01-29
AU2013282400B2 true AU2013282400B2 (en) 2016-02-04

Family

ID=49778522

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013282400A Active AU2013282400B2 (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase
AU2016200460A Active AU2016200460B2 (en) 2012-06-29 2016-01-27 Cells for producing recombinant iduronate-2-sulfatase
AU2018200710A Active AU2018200710B2 (en) 2012-06-29 2018-01-30 Cells for producing recombinant iduronate-2-sulfatase

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016200460A Active AU2016200460B2 (en) 2012-06-29 2016-01-27 Cells for producing recombinant iduronate-2-sulfatase
AU2018200710A Active AU2018200710B2 (en) 2012-06-29 2018-01-30 Cells for producing recombinant iduronate-2-sulfatase

Country Status (27)

Country Link
US (3) US9150841B2 (OSRAM)
EP (1) EP2874649B1 (OSRAM)
JP (3) JP6067849B2 (OSRAM)
KR (1) KR101710487B1 (OSRAM)
CN (2) CN107267460A (OSRAM)
AU (3) AU2013282400B2 (OSRAM)
BR (1) BR112014032560B1 (OSRAM)
CA (1) CA2877521C (OSRAM)
CL (1) CL2014003568A1 (OSRAM)
CO (1) CO7240394A2 (OSRAM)
CR (1) CR20140586A (OSRAM)
DO (1) DOP2014000298A (OSRAM)
EA (2) EA202090805A1 (OSRAM)
ES (1) ES2718346T3 (OSRAM)
GT (1) GT201400302A (OSRAM)
HK (1) HK1209331A1 (OSRAM)
IL (3) IL236343A (OSRAM)
MX (2) MX366155B (OSRAM)
MY (2) MY157086A (OSRAM)
NZ (2) NZ734670A (OSRAM)
PE (1) PE20150957A1 (OSRAM)
PH (2) PH12016500011B1 (OSRAM)
SG (2) SG10201509397SA (OSRAM)
TR (1) TR201904435T4 (OSRAM)
UA (1) UA118955C2 (OSRAM)
WO (1) WO2014005019A2 (OSRAM)
ZA (1) ZA201409396B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6473079B2 (ja) * 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸－２－スルファターゼの機能回復薬剤のスクリーニング方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072275A2 (en) * 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
PT1171615E (pt) 1999-04-26 2007-03-30 Genentech Inc Processo de cultura celular para glicoproteínas
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
EP1212343A4 (en) 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 HUMAN SECRETED PROTEINS
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
JP2004502404A (ja) 2000-02-17 2004-01-29 インサイト・ゲノミックス・インコーポレイテッド ヒトキナーゼ
WO2001070804A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
HUE025101T2 (en) 2002-04-26 2016-02-29 Genentech Inc Purification of proteins other than affinity purification
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
KR20080111487A (ko) 2006-03-20 2008-12-23 메다렉스, 인코포레이티드 단백질 정제 방법
CA3112632A1 (en) 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2011044522A2 (en) * 2009-10-09 2011-04-14 Dow Global Technologies, Inc Adiabatic plug flow reactors and processes incorporating the same
JPWO2011108451A1 (ja) 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
PL3626258T3 (pl) 2010-06-25 2022-01-17 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072275A2 (en) * 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns

Also Published As

Publication number Publication date
EP2874649A2 (en) 2015-05-27
EP2874649B1 (en) 2019-01-02
JP6067849B2 (ja) 2017-01-25
MY189314A (en) 2022-02-04
GT201400302A (es) 2019-05-22
IL274266B (en) 2021-04-29
CO7240394A2 (es) 2015-04-17
AU2016200460B2 (en) 2017-11-02
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
US9150841B2 (en) 2015-10-06
BR112014032560B1 (pt) 2022-04-26
JP6755272B2 (ja) 2020-09-16
PE20150957A1 (es) 2015-07-15
IL236343A (en) 2017-10-31
AU2016200460A1 (en) 2016-02-18
JP2018088933A (ja) 2018-06-14
MX2015000189A (es) 2015-04-08
NZ734670A (en) 2019-12-20
CA2877521A1 (en) 2014-01-03
US9719074B2 (en) 2017-08-01
MX336716B (es) 2016-01-28
EA202090805A1 (ru) 2020-11-30
PH12016500011A1 (en) 2019-08-14
UA118955C2 (uk) 2019-04-10
AU2018200710B2 (en) 2019-11-14
AU2018200710A1 (en) 2018-02-22
WO2014005019A2 (en) 2014-01-03
KR20150030242A (ko) 2015-03-19
US20140004593A1 (en) 2014-01-02
HK1209651A1 (en) 2016-04-08
DOP2014000298A (es) 2015-03-31
NZ703137A (en) 2017-08-25
JP2016105737A (ja) 2016-06-16
WO2014005019A3 (en) 2014-02-27
CL2014003568A1 (es) 2015-04-24
JP2015521848A (ja) 2015-08-03
AU2013282400A1 (en) 2015-01-29
PH12014502868B1 (en) 2015-02-23
EA035511B1 (ru) 2020-06-26
EP2874649A4 (en) 2016-05-04
IL254560B (en) 2020-05-31
CN107267460A (zh) 2017-10-20
CN104540517A (zh) 2015-04-22
ES2718346T3 (es) 2019-07-01
US20160053238A1 (en) 2016-02-25
HK1209331A1 (en) 2016-04-01
US20180010108A1 (en) 2018-01-11
IL254560A0 (en) 2017-11-30
IL274266A (en) 2020-06-30
BR112014032560A2 (pt) 2018-03-06
SG10201509397SA (en) 2015-12-30
ZA201409396B (en) 2018-05-30
JP6302499B2 (ja) 2018-03-28
IL236343A0 (en) 2015-02-26
PH12016500011B1 (en) 2022-07-15
KR101710487B1 (ko) 2017-02-27
CA2877521C (en) 2021-06-01
TR201904435T4 (tr) 2019-05-21
MX366155B (es) 2019-06-28
CR20140586A (es) 2015-04-06
EA201492183A1 (ru) 2015-06-30
PH12014502868A1 (en) 2015-02-23

Similar Documents

Publication Publication Date Title
AU2018200710B2 (en) Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) Method of producing recombinant iduronate-2-sulfatase
JP2021155438A (ja) 組換えヒトｃ１エステラーゼインヒビター及びその使用
EP3220958A1 (en) Lysosomal targeting of enzymes, and uses thereof
HK1209651B (en) Cells for producing recombinant iduronate-2-sulfatase
EA044790B1 (ru) Клетки для получения рекомбинантной идуронат-2-сульфатазы
HK1261383B (en) Recombinant human c1 esterase inhibitor and uses thereof
HK1261383A1 (en) Recombinant human c1 esterase inhibitor and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): SHIRE HUMAN GENETIC THERAPIES, INC.